drugset / Trial / NCT04825574

Study for Patients Previously Treated in Avapritinib Clinical Trials

NCT04825574

Phase 4 Completed 2 enrolled Blueprint Medicines Corporation
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label extension study to provide long term safety data for GIST patients who are deriving clinical benefit from avapritinib upon the completion of avapritinib clinical trials.

Timeline

Start
2021-05-21
Primary completion
2023-11-23
Completion
2023-11-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Avapritinib Small molecule